Please assess the completion status of the following clinical trial:

Trial Title: Does Nightly Dexmedetomidine Improve Sleep and Reduce Delirium in ICU Patients?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18 years~2. Current expectation on the part of the patient's admitting intensivist for patients to require ICU care for \>/= 48 hrs~3. Administered at least one sedative dose (scheduled or prn).~Exclusion Criteria:~1. Patients with delirium (intensive care delirium screening checklist score ≥ 4) or disorientation (not oriented to person and/or place)~2. Patients in whom an ICDSC cannot be reliably completed (e.g. primary language is not French or English, baseline severe hearing impairment)~3. Inability by one of the investigators to obtain informed consent from the legally authorized representative~4. Treating physician refusal~5. Heart rate ≤ 50 BPM~6. Systolic blood pressure ≤ 90 mmHg despite the administration of norepinephrine ≥ 15 mcg/min and/or vasopressin ≥ 0.04 units/min~7. Admission with acute decompensated heart failure~8. History of heart block without pacemaker based on hospital admission note.~9. Acute alcohol withdrawal based on hospital admission note~10. History of end stage liver failure (based on presence of ≥ 1 or more of the following: AST/ALT ≥ 2 times ULN, INR ≥ 2, total bilirubin ≥ 1.5)~11. Irreversible brain disease consistent with severe dementia based on hospital admission note~12. Pregnancy (all women of child-bearing age will undergo a pregnancy test prior to study enrolment)~13. Known allergy or sensitivity to clonidine or dexmedetomidine~14. Current treatment with dexmedetomidine~p. Prognosis considered to be hopeless based on consultation with the ICU admitting physician q. Age ≥80 years r. Currently being managed with a high frequency oscillating mode (HFOV) of mechanical ventilation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Dexmedetomidine (Type: EXPERIMENTAL): Dexmedetomidine 0.2-0.7 mcg/kg/hr from 21:30 to 6:00
- Placebo (Type: PLACEBO_COMPARATOR): Normal Saline 0.2-0.7 mcg/kg/hr from 21:30 to 6:00

Based on this trial design, predict the completion outcome and termination type (if applicable).